Hemostemix Inc. (CVE:HEM) Director Purchases C$30,000.00 in Stock

Hemostemix Inc. (CVE:HEM) Director Peter Alan Lacey bought 200,000 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The shares were bought at an average cost of C$0.15 per share, for a total transaction of C$30,000.00.

Peter Alan Lacey also recently made the following trade(s):

• On Wednesday, February 26th, Peter Alan Lacey sold 96,464 shares of Hemostemix stock. The stock was sold at an average price of C$0.18, for a total value of C$16,881.20.

Hemostemix Price Performance

CVE:HEM opened at C$0.14 on Monday. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48. The company has a 50 day moving average price of C$0.22 and a 200-day moving average price of C$0.13. Hemostemix Inc. has a 1-year low of C$0.04 and a 1-year high of C$0.43. The firm has a market cap of C$20.40 million, a price-to-earnings ratio of -4.08 and a beta of 0.20.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.